Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 223 in CKD patients on hemodialysis with hyperphosphatemia
NCT00530114Phase 2Completed
- Sponsor
- Amgen
- Start
- Mar 2008
- Primary completion
- Nov 2008
01
Overview
Phase 2, randomised, double-blind trial in hyperphosphatemia comparing AMG 223 with Placebo (2 arms). Primary endpoint: Reduction in serum phosphorus at 3 weeks. Started Mar 2008; status: completed.
02
Drugs
bixalomer
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00530114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00530114.